Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade

• Status: Not yet recruiting
• Trial end date: 2021-12-20
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study will be to evaluate by means of a prospective randomized clinical trial, the time required for the reversal of moderate neuromuscular blockade (NMB) (Train-of-four count = 3; TOFc 3) to Train-of-four ratio (TOFr) > 0.9 and TOFr = 1.0 after administration of different doses of neostigmine (30, 50 and 70 mcg/kg) in patients undergoing general anesthesia with propofol or sevoflurane. In addition, the probability of NMB reversal in less than 10 minutes or 15 minutes after neostigmine administration will be registered.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pontificia Universidade Catolica de Sao Paulo
• Treatments: Anesthetics; Neostigmine; Sevoflurane

Criteria

Inclusion Criteria:

• Patients physical status according to the American Society of Anesthesiologists I and II

• submitted to nose or ear surgeries under general anesthesia

Exclusion Criteria:

• Refusal to participate in the study

• Presence of kidney, liver or neuromuscular disease

• Contraindication to the use of any of the drugs used in the study

• Body mass index (BMI) ≥ 30.